Telitacicept
Based on 1 Customer Validation
Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease. The component ratio of this product is Active ingredient : Excipients = 1: 0.5-1: 0.8.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.30%
- CAS No.: 2136630-26-5
- Masse moléculaire:75.36 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform TNF Receptor
More
Activité biologique
Description
IC50 & Target
(BLyS)/APRIL[1]
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MOG35-55 peptide-induced EAE mice model (6- to 8-week-old, female)[2]
-
Dosage:15mpk and 7.5mpk
-
Administration:i.p.
-
Result:Reduced the severity of tail paralyses and limb weakness in mice, but not as high efficacy as equal dose of Secukinumab (HY-P9927).
Decreased the number of infiltrating inflammatory cells around the white matter in spinal cord.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
[TNFRSF13B (tumor necrosis factor receptor (TNFR)superfamily member 13B, TACI, transmembrane activator and CAML Interactor)]2-IGHG1 Fc (Fragment constant)
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized BAFF/TNFSF13B Protein, Human (CHO, HY-P7003) can bind Telitacicept. The EC50 for this effect is 14.06 ng/mL.
Chemical Information
-
CAS No. 2136630-26-5
-
Appearance Solid
-
Masse moléculaire 75.36 kDa
-
Color White to off-white
-
SMILES
[Telitacicept]
-
Synonyms
RC18
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)